Goserelin Acetate with or without Antiandrogen or Estrogen in the Treatment of Patients with Advanced Prostate Cancer: A Multicenter, Randomized, Controlled Trial in Japan

Objective: The aims of this randomized, controlled study were to investigate the efficacy and safety of long-term monotherapy with the luteinizing hormone-releasing hormone agonist goserelin acetate compared with both short- and long-term combined androgen blockade. Methods: Patients with advanced p...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 1999-11, Vol.29 (11), p.562-570
Main Authors: Kotake, Toshihiko, Usami, Michiyuki, Akaza, Hideyuki, Koiso, Kenkichi, Homtna, Yukio, Kawabe, Kazuki, Aso, Yoshio, Orikasa, Seiichi, Shimazaki, Jun, Isaka, Shigeo, Yoshida, Osamu, Hirao, Yoshihiko, Okajima, Eigoro, Naito, Seiji, Kumazawa, Joichi, Kanetake, Hiroshi, Saito, Yutaka, Ohi, Yoshitada, Ohashi, Yasuo
Format: Article
Language:English
Subjects:
antiandrogen
chlormadinone acetate
diethylstilbestrol diphosphate
goserelin acetate
prostate cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The aims of this randomized, controlled study were to investigate the efficacy and safety of long-term monotherapy with the luteinizing hormone-releasing hormone agonist goserelin acetate compared with both short- and long-term combined androgen blockade. Methods: Patients with advanced prostate cancer (n = 371) were randomized to treatment with goserelin acetate alone or a combination of goserelin acetate plus either long-term or short-term antiandrogen (chlormadinone acetate) or short-term estrogen (diethylstilbestrol diphosphate). Results: There were no significant differences between the treatment groups with respect to objective progression, overall survival or disease-specific survival. Nevertheless, subgroup analysis suggested that patients with minimal disease or a good prognosis might benefit more from combined androgen blockade than other patients. Combined androgen blockade significantly reduced the incidence of disease flare compared with goserelin acetate treatment alone. Conclusions: Neither short- nor long-term combined androgen blockade had a survival advantage over goserelin acetate alone.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/29.11.562